(2S)-2-methylpiperazine-1,4-dicarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (2S)-2-methylpiperazine-1,4-dicarboxylic acid
• 化学式: C₇H₁₂N₂O₄
• 分子量: 188.18
• InChiKey: GKGLJFWUEIMDKN-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Heteroaromatic modulators of the retinoid-related orphan receptor gamma
  申请人：LEO PHARMA A/S

  公开号：US10662181B2

  公开（公告）日：2020-05-26

  The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

  本发明涉及一种符合通式 (I) 的化合物 其中 X 代表 N 或 CH；R1 是-CN、(C1-C6)烷基、(C3-C7)环烷基、(3-7 位)杂环烷基、(5-6 位)杂芳基、(C3-C7)环烷基-(C1-C4)烷基、(3-7 位)杂环烷基-(C1-C4)烷基或(5-6 位)杂芳基-(C1-C4)烷基；R2 是卤素、氰基、(C1-C4)烷基或(C3-C7)环烷基；R3是卤素、氰基、(C1-C4)烷基、(C1-C4)卤代烷基或(C3-C7)环烷基； R4是(C1-C4)烷基或(C1-C4)卤代烷基； R5是(C1-C6)烷基、(C3-C7)环烷基、(C1-C6)烷基-(C3-C7)环烷基、(C3-C7)环烷基-(C1-C6)烷基、(3-7位)杂环烷基、苯基、(5-6位)杂芳基或-ORa。本发明还涉及用于治疗的上述化合物、包含上述化合物的药物组合物以及制备上述化合物的中间体。
• HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA
  申请人：Leo Pharma A/S

  公开号：EP3484880B1

  公开（公告）日：2020-09-02
• HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA
  申请人：LEO PHARMA A/S

  公开号：US20200291010A1

  公开（公告）日：2020-09-17

  The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R 1 is —CN, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C 3 -C 7 )cycloalkyl(C 1 -C 4 )alkyl, (3-7 membered)heterocycloalkyl-(C 1 -C 4 )alkyl or (5-6 membered)heteroaryl-(C 1 -C 4 )alkyl; R 2 is halogen, cyano, (C 1 -C 4 )alkyl or (C 3 -C 7 )cycloalkyl; R 3 is halogen, cyano, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl or (C 3 -C 7 )cycloalkyl; R 4 is (C 1 -C 4 )alkyl or (C 1 -C 4 )haloalkyl; R 5 is (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 6 )alkyl-(C 3 -C 7 )cycloalkyl, (C 3 -C 7 )cycloalkyl-(C 1 -C 6 )alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —OR a . The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.